JE Vaccine Singapore.
JE Vaccine Singapore: Japanese encephalitis virus (JEV) vaccine jab/shot/injection schedule, to vaccinate against the Japanese encephalitis virus (JEV), to immunise against Japanese encephalitis (JE) clinic, Singapore. Private and confidential service. Definitions, references, and latest news.
The inactivated mouse-brain-derived (IMB) vaccine is now commonly replaced by cell-culture-based vaccines. The live attenuated SA 14-14-2 vaccine is widely used in China and in an increasing number of countries within the Asian region, including India, the Republic of Korea, Sri Lanka, and Thailand.
A Vero cell-derived, inactivated JE vaccine was approved in 2009 in North America, Australia and various European countries. The vaccine is based on the attenuated SA 14-14-2 JE viral strain, inactivated and alum-adjuvanted. The primary two doses are administered 4 weeks apart. A booster dose is recommended 1–2 years after the primary immunization. This vaccine has been given concomitantly with hepatitis A vaccine without significant interference with safety and immunogenicity. Data on concomitant administration with other vaccines frequently used in travellers are currently unavailable. The vaccine is licensed for use in individuals 17 years of age and older in the United States, and 18 years and above in other countries. Post-marketing safety studies are under way.
Another Vero cell-derived inactivated JE vaccine was licensed by the Japanese authorities in February 2009 and a similar vaccine was licensed in 2011. These two vaccines use the same strain of JE virus (Beijing-1) as the mouse-brain-derived vaccine. Clinical trials have shown that the vaccines are safe and immunogenic, with seroconversion rates exceeding 95%. Theses vaccines are currently not available outside Japan.
In addition, a new live attenuated, JE-yellow fever chimeric vaccine has recently been licensed in Australia and Thailand , and will be commercialized from 2012. This vaccine requires a single dose for primary immunization; the possible need for booster doses remains to be determined.
Precautions and contraindications
A hypersensitivity reaction to a previous dose is a contraindication. The live attenuated vaccine should be avoided in pregnancy unless the likely risk favours its administration. Rare, but serious, neurological adverse events attributed to IMB vaccine have been reported from countries or areas at risk as well as from non-risk countries or areas. Allergic reactions to components of the vaccine occur occasionally. As such reactions may occur up to 2 weeks after administration, it is advisable to ensure that the complete course of vaccine is administered well in advance of departure.
| Type of vaccine:|
1) Live attenuated vaccine (SA 14-14-2 strain)
2) Inactivated, Vero cell-derived, alum-adjuvanted vaccine (SA 14-14-2 strain)
3) Inactivated Vero cell-derived based vaccines (Beijing-1 strain)
Booster: The duration of immunity is not well established for the above vaccines. For 1) the live attenuated vaccine, a booster dose is recommended in some countries. For 2) the Japanese vaccines, a booster is recommended after year 1, and thereafter every 3 years. For 3) the inactivated, alum-adjuvanted vaccine, one booster is recommended 12–14 months after completion of the primary immunization; the possible need for further boosters to be determined.
Contraindications: For all JE vaccines: hypersensitivity to a previous dose of vaccine. For live JE vaccine: pregnancy and immunosuppression.
Adverse reactions: Occasional mild local or systemic reactions
Before departure: The immunization series should be completed at least 1 week before potential exposure to JEV.
Special precautions: With the inactivated, alum-adjuvanted, Vero cell-derived SA14-14-2 vaccine, safety and effectiveness have not been established in pregnant women, in nursing mothers, or in children and adolescents (younger than 17 years of age).
|Dose schedule||Price |
|Varilrix™|| Varicella zoster virus |
|Zostavax™||Herpes zoster Shingles||≥50y||1||$295/=|
|Stamaril®||Yellow fever virus||Yellow fever||9m-59y||1||10 yearly||$250/=|
|Inactivated / Whole / Viral & Bacterial|
|Rabipur®||Rabies virus||Rabies||any||3||d 0, 7, & 21 or 28||$call/=|
|Ixiaro®||Japanese encephalitis virus||Japanese encephalitis||≥17y||2||2nd: 28d after 1st||$386/=|
|1||Booster: 12-24m after 2nd|
|Dukoral®||Vibrio cholerae||Cholera||2-6y||3||1-6w interval||$113/=|
|1||Booster: 6m after 3rd|
|1||Booster: 2y after 2nd|
|Inactivated / Fractional / Protein|
|Intanza™||Influenza virus||Influenza||18-59y||1||1 yearly||$30/=|
|Fluarix™||Influenza virus||Influenza||6-36m||½||1 yearly||$30/=|
|Tetavax||Clostridium tetani||Tetanus||adults||3||1-2m interval |
3rd @ 6-12m
|Bordetella pertussis||Pertussis |
|Inactivated / Fractional / Polysaccharide / Pure|
|Typhim Vi®||Salmonella typhi||Typhoid fever||>5y||1||3 yearly||$48/=|
|Mencevax® ACWY||Neisseria meningitidis |
types A, C, W-135
|Inactivated / Fractional / Polysaccharide / Conjugate|
|Menactra®||Neisseria meningitidis |
types A, C, W-135
| Prevenar 13® (SG) / |
Prevnar 13® (US)
|Streptococcus pneumoniae |
types 1, 3, 4, 5,
6A, 6B, 7F, 9V, 14,
18C, 19A, 19F, 23F
|Pneumococcal infection||6w-6m||4||1m interval |
4th @ 12-15m
If the clinic attendance is just for vaccination alone, no additional consultation fees are charged.
Testing for immunity against the following is available:
|Varicella zoster virus||Varicella Zoster IgG Antibody||$44/=|
|Measles virus||Measles IgG Antibody||$90/=|
|Rubella virus||Rubella IgG Antibody||$24/=|
|Hepatitis A virus||Hepatitis A IgG Antibody||$30/=|
|Hepatitis B virus||Hepatitis B surface Antibody||$10/=|
Other vaccines not stocked
- Haemophilus influenzae type b Vaccine / HIB Vaccine
- Polio Vaccine
- Rotavirus Vaccine
- Tuberculosis Vaccine / TB Vaccine / BCG Vaccine
- Tick-Borne Encephalitis Vaccine / TBE Vaccine
- Live attenuated
- Hajj and Umrah Health Requirements
- Memish ZA. The Hajj: communicable and non-communicable health hazards and current guidance for pilgrims. Euro Surveill. 2010;15(39)
- Memish Z.A., Goubeaud A., Broker M., Malerczyk C., Shibl A.M. Invasive meningococcal disease and travel. J Infect Public Health. 2010;3(4):143-151.
|Dose schedule||Price |
|Havrix™ 1440 Adult||Hepatitis A virus||Hepatitis A||≥19y||2||m 0 & 6-12||$90/=|
|Twinrix®||Hepatitis A virus |
Hepatitis B virus
|Hepatitis A |
|1-15y||2||m 0, 6-12||$135/=|
|≥16y||3||m 0, 1, 6|
|4||d 0, 7, 21 & m 12|
|Inactivated / Fractional / Protein / Subunit / Recombinant|
|Engerix™-B 20 μg||Hepatitis B virus||Hepatitis B||11-15y||2||m 0, & 6||$50/=|
|≥20y||3||m 0, 1, & 6|
|4||m 0, 1, 2, & 12 or |
d 0, 7, 21 & m 12
types 6, 11, 16, & 18
| Genital warts |
|9-26y||3||m 0, 2, & 6 or |
m 0, 1, & 4
types 16, & 18
(31, 33, & 45)
|10-25y||3||m 0, 1, & 6 |
m 0, 1, & 5
m 0, 2½, 12
types 6, 11, 16, 18,
31, 33, 45,
52, & 58
|3||m 0, 2, & 6 or |
m 0, 1, & 4
For persons aged 0 to <18 years
|Vaccination against||Birth||1 month||3 months||4 months||5 months||6 months||12 months||15 months||18 months||6-7 years^||10-11 years^^|
|Hepatitis B||HepB (D1)||HepB (D2)||HepB (D3)#|
|Diphtheria, Tetanus, Pertussis||DTaP (D1)||DTaP (D2)||DTaP (D3)||DTaP (B1)||Tdap (B2)|
|Poliovirus||OPV (D1)||OPV (D2)||OPV (D3)||OPV (B1)||OPV (B2)||OPV (B3)|
|Measles, Mumps, Rubella||MMR (D1)||MMR (D2)##|
|Pneumococcal Disease||PCV (D1)||PCV (D2)||PCV (B1)|
|Human Papillomavirus||Recommended for females 9 to 26 years; three doses are required at intervals of 0, 2, 6 months|
|Influenza||Recommended annually for all children aged 6 months to <5 years and children aged 6 months to <18 years in high-risk groups|
- National Childhood and Adolescent Immunisation Schedule, Singapore For persons aged 0 to <18 years
- Infectious Diseases (Diphtheria and Measles Vaccination) Regulations